Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

28. juni 2026 oppdatert av: Liping Dou

A Single-arm, Open-label, Phase I Clinical Study of Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.

Studieoversikt

Detaljert beskrivelse

This study is a single-center, prospective, single-arm Phase I clinical trial. Since July 2023, 12 patients with high-risk acute B-lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation were enrolled at the Department of Hematology, the PLA General Hospital . Patients were enrolled after 45d for MSD-HSCT, and after 60d for URD/Haplo donor-HSCT. The maintenance regimen combined blinatumomab (9 µg/day × 7 days) and donor lymphocyte infusion (DLI, CD3+ cells 1× 10⁵/kg). The first cycle was given within the first 3 months after allogeneic HCT and then at approximately 6, 9, and 12 months following transplant. The safety and efficacy of this regimen were analyzed. Patients were premedicated with dexamethasone prior to the start of each cycle. The study was approved by the Ethics Committee of the PLA General Hospital.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Beijing, Kina
        • Rekruttering
        • Chinese PLA General Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • 1) Voluntary participation: The participant or legal guardian fully understands this clinical study, provides informed consent (ICF), and is willing/able to comply with all trial procedures.

    2) Age: <70 years old at screening, any gender. 3) Diagnosis: High-risk acute B-lymphoblastic leukemia (B-ALL) with MRD-negative status post-transplant. High-risk factors include:

    • >CR1 status
    • Pre-transplant MRD+ status
    • Ph-like subtype
    • KMT2A rearrangement
    • Other high-risk cytogenetic/genetic factors per ELN 2023 criteria. 4) Allergy: No history of severe allergies. 5) Liver function: ALT and AST ≤ 2.5 × ULN; Total bilirubin ≤ 2 × ULN. 6) Renal function: Serum creatinine ≤ ULN. 7) Other conditions: Absence of uncontrolled infections or severe psychiatric disorders.

      8) Performance status: ECOG score 0-3, with life expectancy ≥ 4 months. 9) MRD status: Bone marrow flow cytometry confirmed MRD-negative before enrollment.

      10) Engraftment: Evidence of myeloid and platelet engraftment. 11) GVHD: No active graft-versus-host disease (GVHD).

Exclusion Criteria:

  • 1) Drug hypersensitivity/contraindications: Patients with known allergies or contraindications to the investigational drug(s).

    2) Pregnancy/lactation: Pregnant or breastfeeding female patients. 3) Active infection/GVHD: Patients with active infection or active graft-versus-host disease (GVHD).

    4) Substance abuse: Patients with chronic heavy smoking or alcohol use that may interfere with clinical evaluation.

    5) Impaired consent/compliance: Patients unable to provide informed consent or comply with procedures due to psychiatric/neurological disorders.

    6) Recent major surgery: Patients who underwent major organ surgery within the past 6 weeks.

    7) Organ dysfunction:

  • Liver: ALT or AST > 2.5 × ULN; Total bilirubin > 2 × ULN
  • Kidney: Serum creatinine > ULN 8) Investigator judgment: Patients deemed ineligible by investigators (e.g., poor compliance, substance abuse).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: BLINA+DLI
blinatumomab 9ug d1-7, 28ug d8-14, DLI ( CD3+cell 1×10^5/kg)
blinatumomab 9ug d1-7, 28ug d8-14
CD3+cell 1×10^5/kg

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
1 year progression-free-survival
Tidsramme: 1 year
the percentage of patients who remain alive and whose disease has not gotten relapse one full year after they started treatment.
1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
1 year aGVHD rate
Tidsramme: 100 days after transplantation
Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria) The cumulative incidences of aGvHD was defined as the number and the ratio of the participants with aGVHD.
100 days after transplantation
1 year cGVHD rate
Tidsramme: 365 days after transplantation
Number of participants with cGVHD as assessed by chronic graft versus host disease grading criteria (refer to NIH criteria) cGvHD was diagnosed and graded according to the 2014 National Institutes of Health (NIH) consensus criteria: mild, moderate or severe respectively.
365 days after transplantation
Nonrelapse mortality (NRM)
Tidsramme: 365 days after transplantation
Defined as the proportion of subjects who died due to causes other than malignancy relapse
365 days after transplantation
Overall survival (OS)
Tidsramme: 365 days after transplantation
Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause
365 days after transplantation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2024

Primær fullføring (Antatt)

30. november 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

16. juni 2026

Først innsendt som oppfylte QC-kriteriene

28. juni 2026

Først lagt ut (Faktiske)

1. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • BLINADLISTUDY

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere